With oncolytic virus therapeutics continuing to demonstrate their clinical potential in immuno-oncology, they have become hot commodities with companies looking to gain a foothold in the space. As a result, biotechnology companies with promising technologies are attracting the attention of major biopharmaceutical companies. In part 2 of our feature on oncolytic viruses, we examine the deals landscape in this area, which in the past 12 months has generated a number of major transactions involving big pharma companies.